2026– date –
-
GLP-1 Drug Manufacturing Surges: CDMOs Scale Peptide Synthesis, Driving Technology Transfer
IntuitionLabs USA Overview Driven by soaring GLP-1 demand, Contract Development and Manufacturing Organizations (CDMOs) are rapidly expanding peptide synthesis capabilities. Industry reports project the GLP-1 peptide CDMO market to grow ... -
Samsung Biologics Labor Dispute Stalls Wage Talks, Raising Concerns for Global CDMO Competitiveness
The Elec Inc. South Korea Overview Wage negotiations between management and labor union at Samsung Biologics have reached a prolonged stalemate, raising concerns about the company's global competitiveness in the Contract Development and ... -
Polpharma Biologics and Tuteur Forge Alliance to Boost Biosimilar Access Across Latin America
Morningstar ポーランド Overview Polpharma Biologics has finalized a strategic licensing agreement with Argentina's Tuteur Pharmaceutical, granting exclusive commercialization rights for a biosimilar targeting autoimmune diseases across L... -
Thousand Oaks Biologics Honored with Forbes China Industry Award for Leading ADC CDMO Capabilities
TMX Newsfile China Overview Thousand Oaks Biologics has been awarded the "2026 Forbes China Industry Development Leading Enterprise Award" for its advanced capabilities in antibody-drug conjugate (ADC) manufacturing. Operating across Chi... -
FDA Grants Breakthrough Therapy Designation to Chronic Low Back Pain Treatment, Signaling Potential Shift for Cannabinoid-Derived Therapies
YouTube (CB1 Capital) USA Overview The U.S. FDA has granted Breakthrough Therapy Designation (BTD) for a treatment for chronic low back pain. This announcement potentially signals an emerging wave of designations for cannabinoid-derived ... -
Wave Life Sciences Reports Positive RNA Editing Clinical Data for WVE-006 in Alpha-1 Antitrypsin Deficiency (AATD)
BioPharm International USA Overview Wave Life Sciences announced favorable clinical data from the RestorAATion-2 trial of WVE-006, an RNA editing therapeutic for Alpha-1 Antitrypsin Deficiency (AATD). WVE-006, a GalNAc-conjugated RNA edi... -
Eli Lilly Acquires Engage Biologics for Up to $202 Million to Strengthen Non-Viral DNA Delivery Platform
GuruFocus USA Overview Eli Lilly has agreed to acquire Engage Biologics for up to $202 million, aiming to leverage Engage’s innovative non-viral DNA delivery platform and accelerate the development of next-generation gene therapies. Enga... -
Isomorphic Labs Secures $2.1 Billion to Scale AI Drug Discovery Engine, Eyes First AI-Designed Drug in Human Trials by Year-End
AI Healthcare News USA Overview Isomorphic Labs, Alphabet's AI drug discovery arm, has raised a staggering $2.1 billion to expand its "IsoDDE" AI engine. Leveraging AI in conjunction with AlphaFold 3, the company develops a platform to p... -
Immunai and AstraZeneca Expand Oncology AI Partnership for Third Time, Valued at Up To $37.5 Million
WTWH Media USA Overview Immunai, a startup building foundation models for the human immune system, has announced a third expansion of its oncology partnership with AstraZeneca, entitling Immunai to up to $37.5 million through 2027. This ... -
Incyte and Genesis Molecular AI Expand Partnership to Accelerate AI-Driven Drug Discovery with Over $1 Billion in Milestones
Forbes USA Overview Incyte has significantly expanded its strategic collaboration with Genesis Molecular AI, integrating AI platforms with proprietary experimental data to accelerate novel molecule discovery. This enhanced partnership, p...
